Transdermal Drug Delivery Market-our new study reveals current trends, technological advancements, and predicted revenues
Where the Transdermal Drug Delivery market is heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 210+ page report provides 150+ tables, 150+ charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Transdermal Drug Delivery market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors
– You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.
Report Scope
Global Transdermal Drug Delivery market 2021-2031 is segmented on the basis of Technology, Application and Geography.
• Revenue and growth forecasts from 2021 to 2031 for the Global Transdermal Drug Delivery Market by Technology:
– Electroporation
– Radiofrequency
– Iontophoresis
– Microporation
– Thermal
– Mechanical Arrays
– Ultrasound
– Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Transdermal Drug Delivery Market by Application:
–CNS
– Pain Management
– Cardiovascular
–Hormone
–Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Transdermal Drug Delivery Market by Region:
– North America: US, Canada
– Europe: Germany, UK, Italy, France, Spain, Rest of Europe
– Asia-Pacific: China, India, Japan, Australia, Rest of Asia-Pacific
– Latin America: Brazil, Mexico, and Rest of Latin America
– Middle East & Africa: GCC, South Africa, Rest of MEA
• Our study discusses the selected leading companies that are the major players in the Transdermal Drug Delivery industry:
– Novartis AG
– Johnson & Johnson
– Mylan Pharmaceuticals, Inc
– Boehringer Ingelheim GmbH
–Biogel Technology, Inc.
– Transdermal Technologies, Inc.
– Skyepharma PLC
– Watson Pharmaceuticals, Inc
–3M Company
– Noven Pharmaceuticals, Inc
–4P Therapeutics, LLC
–Echo Therapeutics, Inc
–Transdermal Corp
How the Transdermal Drug Delivery Market report helps you
In summary, our 190+ page report provides you with the following knowledge:
– Revenue forecasts to 2031 for each of the above mentioned segments each forecasted at a global and regional level– growth of all segments on regional level helps to understand most lucrative segment.
– Revenue forecasts to 2031 for 5 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.
– Prospects for established firms and those seeking to enter the market– including company profiles for over 10 of the major companies involved in the Transdermal Drug Delivery market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
COVID 19 Impact & Recovery Analysis on the Market
Currently, COVID-19 (Coronavirus) is prevalent across the globe. Many companies are underway to discover a vaccine, or therapeutics which can prevent or cure the COVID-19 virus. According to the World Health Organization, as of 13th September 2020, there were over 28,637,952 confirmed cases of COVID-19, with more than 917,417 deaths, globally.
The COVID-19 disease is continuously disrupting the growth of various markets. However, the immediate effect of the pandemic is different. Some industries will register a drop in demand, various other markets will remain unchanged and display a promising growth opportunities. The healthcare centers, such as hospitals and diagnostic labs, have been investing heavily in maintaining the supply of essential equipment and drugs. Due to lockdown across the globe, people were unable to reach healthcare facilities and non-urgent procedures were advised to put hold which impacted the healthcare industry a lot.
Due to COVID 19 pandemic patients were reluctant in visiting hospitals or clinics for their treatments and preferred virtual doctor visits. Lockdown across the globe due to the pandemic led to the delay of procedures which were not urgent. These factors negatively impacted the transdermal drug delivery market for limited period of time. However, slowly the situation is getting back to normal everywhere and the market discussed is expected to increase in future.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Transdermal Drug Delivery market and leading companies. You will find data, trends and predictions.
The Transdermal Drug Delivery Market 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Transdermal Drug Delivery industry.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Transdermal Drug Delivery Market Report 2021-2031: Forecasts by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User (Homecare settings, Hospitals and Clinics). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated VISIONGAIN Reports
1.8. About VISIONGAIN
2. Introduction to the Transdermal Drug Delivery Market
2.1. Transdermal Drug Delivery Market Definition
2.2. Application Submarkets Definitions
2.3. Type Submarkets Definitions
2.4. End User Submarkets Definitions
3. Transdermal Drug Delivery Market Overview
3.1. Transdermal Drug Delivery Market Size and Forecast by Region
3.2. Transdermal Drug Delivery Market Share by Region
3.2.1. Market Dynamics
3.2.1.1. Growing Incidence of Chronic Diseases
3.2.2. Restraints
3.2.2.1. Drug Failure and Memories of Transdermal Drug Delivery Systems
3.2.3. Opportunities
3.2.3.1. Self-Administration and Homebased Care Drug Distribution Systems
3.2.4. Trends
3.2.4.1. Practical Fences Connected to Skin Annoyance and Penetrability
3.3. SWOT Analysis
3.3.1. Strengths
3.3.1.1. Strength 1
3.3.2. Weaknesses
3.3.2.1. Weakness 1
3.3.3. Opportunities
3.3.3.1. Opportunity 1
3.3.4. Threats
3.3.4.1. Threat 1
3.4. Porter’s Five Forces Analysis
3.4.1. Competitive Rivalry
3.4.2. Supplier Power
3.4.3. Buyer Power
3.4.4. Threat of Substitution
3.4.5. Threat of New Entry
4. GlobalTransdermal Drug Delivery Market Analysis and Forecast 2021-2031, by Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Pain management
4.3. Hormonal application
4.4. Cardiovascular diseases
4.5. Central Nervous system disorders
4.6. Other Applications
5. GlobalTransdermal Drug Delivery Market Analysis and Forecast, 2021-2031 by Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.2. Transdermal Patches
5.3. Transdermal Semisolids
6. GlobalTransdermal Drug Delivery Market Analysis and Forecast, 2021-2031 byEnd users (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. Home care settings
6.3. Hospitals and Clinics
7. North America Transdermal Drug Delivery MarketAnalysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Transdermal Drug Delivery Market Size and Forecast byApplication
7.3. North America Transdermal Drug Delivery Market Size and Forecast by Type
7.4. North America Transdermal Drug Delivery Market Size and Forecast by End User
7.5. U.S. Transdermal Drug Delivery Market
7.6. Canada Transdermal Drug Delivery Market
8. EuropeTransdermal Drug Delivery Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Transdermal Drug Delivery Market Size and Forecast by Application
8.3. Europe Transdermal Drug Delivery Market Size and Forecast by Type
8.4. Europe Transdermal Drug Delivery Market Size and Forecast by End User
8.5. UK Transdermal Drug Delivery Market
8.6. Germany Transdermal Drug Delivery Market
8.7. France Transdermal Drug Delivery Market
8.8. Rest of Europe Transdermal Drug Delivery Market
9. Asia PacificTransdermal Drug Delivery Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Transdermal Drug Delivery Market Size and Forecast by Application
9.3. Asia Pacific Transdermal Drug Delivery Market Size and Forecast by Type
9.4. Asia Pacific Transdermal Drug Delivery Market Size and Forecast by End User
9.5. China Transdermal Drug Delivery Market
9.6. India Transdermal Drug Delivery Market
9.7. Japan Transdermal Drug Delivery Market
9.8. Rest of Asia Pacific Transdermal Drug Delivery Market
10. Latin AmericaTransdermal Drug Delivery Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Transdermal Drug Delivery Market Size and Forecast by Application
10.3. Latin America Transdermal Drug Delivery Market Size and Forecast by Type
10.4. Latin America Transdermal Drug Delivery Market Size and Forecast by End User
10.5. Brazil Transdermal Drug Delivery Market
10.6. Mexico Transdermal Drug Delivery Market
10.7. Rest of Latin America Transdermal Drug Delivery Market
11. MEATransdermal Drug Delivery Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Transdermal Drug Delivery Market Size and Forecast by Application
11.3. MEA Transdermal Drug Delivery Market Size and Forecast by Type
11.4. MEA Transdermal Drug Delivery Market Size and Forecast by End User
11.5. GCC Transdermal Drug Delivery Market
11.6. South Africa Transdermal Drug Delivery Market
11.7. Rest of MEA Transdermal Drug Delivery Market
12. Companies in the Transdermal Drug Delivery Market
12.1. Hisamitsu Pharmaceutical Co., Inc.
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Mylan N.V.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. UCB S.A
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Novartis AG
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. GlaxoSmithKline PLC
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Boehringer Ingelheim International GmbH.
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Johnson & Johnson (J&J)
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. Endo International, Inc
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. Purdue Pharma L.P.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. Lavipharm
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated VISIONGAIN Reports
VISIONGAIN Report Sales Order Form
Appendix A
About VISIONGAIN
Appendix B
VISIONGAIN report evaluation form
LIST OF TABLES
Table No 1: Transdermal Drug Delivery Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 2: Transdermal Drug Delivery Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 3: Transdermal Drug Delivery Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 4: Transdermal Drug Delivery Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 5: Transdermal Drug Delivery Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 6: Transdermal Drug Delivery Market Drivers & Restraints 2020
Table No 7: Transdermal Drug Delivery Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 8: Transdermal Drug Delivery Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 9: Transdermal Drug Delivery Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 10: Transdermal Drug Delivery Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 11: Transdermal Drug Delivery Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 12: Pain management Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 13: Pain management Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 14: Pain management Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 15: Pain management Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 16: Pain management Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 17: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 18: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 19: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 20: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 21: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 22: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 23: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 24: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 25: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 26: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 27: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 28: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 29: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 30: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 31: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 32: Transdermal Drug Delivery Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 33: Transdermal Drug Delivery Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 34: Transdermal Drug Delivery Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 35: Transdermal Drug Delivery Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 36: Transdermal Drug Delivery Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 37: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 38: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 39: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 40: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 41: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 42: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 43: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 44: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 45: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 46: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 47: Transdermal Drug Delivery Forecast by End users 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 48: Transdermal Drug Delivery Forecast by End users 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 49: Transdermal Drug Delivery Forecast by End users 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 50: Transdermal Drug Delivery Forecast by End users 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 51: Transdermal Drug Delivery Forecast by End users 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 52: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 53: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 54: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 55: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 56: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 57: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 58: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 59: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 60: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 61: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 62: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 63: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 64: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 65: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 66: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 67: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 68: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 69: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 70: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 71: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 72: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 73: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 74: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 75: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 76: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 77: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 78: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 79: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 80: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 81: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 82: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 83: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 84: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 85: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 86: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 87: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 88: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 89: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 90: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 91: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 92: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 93: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 94: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 95: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 96: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 97: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 98: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 99: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 100: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 101: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 102: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 103: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 104: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 105: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 106: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 107: Asia Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 108: Asia Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 109: Asia Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 110: Asia Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 111: Asia Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 112: Asia Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 113: Asia Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 114: Asia Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 115: Asia Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 116: Asia Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 117: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 118: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 119: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 120: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 121: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 122: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 123: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 124: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 125: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 126: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 127: India Military Aircraft Fleet (Aircraft Application, Number of Aircraft)
Table No 128: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 129: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 130: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 131: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 132: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 133: Japan Military Aircraft Fleet (Aircraft Application, Number of Aircraft)
Table No 134: RoAPAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 135: RoAPAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 136: RoAPAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 137: RoAPAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 138: RoAPAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 139: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 140: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 141: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 142: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 143: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 144: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 145: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 146: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 147: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 148: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 149: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 150: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 151: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 152: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 153: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 154: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 155: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 156: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 157: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 158: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 159: Rest of Latin America Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 160: Rest of Latin America Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 161: Rest of Latin America Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 162: Rest of Latin America Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 163: Rest of Latin America Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 164: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 165: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 166: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 167: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 168: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 169: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 170: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 171: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 172: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 173: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 174: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 175: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 176: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 177: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 178: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 179: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 180: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 181: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 182: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 183: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 184: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table No 185: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 186: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 187: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 188: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 189: Leading 10 Fiber Optic Network Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table No 190: UCB S.A Co., Inc. Profile (CEO, HQ, Founded, Website)
Table No 191: UCB S.A Co., Inc. (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 192: UCB S.A Co., Inc. (Net Income 2016-2019 (US$mn, AGR %)
Table No 193: Mylan N.V Profile (CEO, HQ, Founded, Website)
Table No 194: Mylan N.V (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 195: Mylan N.V (Net Income 2016-2019 (US$mn, AGR %)
Table No 196: UCB S.A. Profile (CEO, HQ, Founded, Website)
Table No 197: UCB S.A. (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 198: UCB S.A. (Net Income 2016-2019 (US$mn, AGR %)
Table No 199: Novartis AG. Profile (CEO, HQ, Founded, Website)
Table No 200: Novartis AG. (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 201: Novartis AG. (Net Income 2016-2019 (US$mn, AGR %))
Table No 202: Glaxosmithkline PLC Profile (CEO, HQ, Founded, Website)
Table No 203: Glaxosmithkline PLC Profile (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 204: Glaxosmithkline PLC Profile (Net Income 2016-2019 (US$mn, AGR %))
Table No 205: Boehringer Ingelheim International GmbH Profile (CEO, HQ, Founded, Website)
Table No 206: Boehringer Ingelheim International GmbH (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 207: Boehringer Ingelheim International GmbH (Net Income 2016-2019 (US$mn, AGR %))
Table No 208: Johnson & Johnson (J&J). Profile (CEO, HQ, Founded, Website)
Table No 209: Johnson & Johnson (J&J). (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 210: Johnson & Johnson (J&J). (Net Income 2016-2019 (US$mn, AGR %))
Table No 211: UCB S.A. Profile (CEO, HQ, Founded, Website)
Table No 212: UCB S.A. (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 213: UCB S.A. (Net Income 2016-2019 (US$mn, AGR %))
Table No 214: Purdue Pharma L.P. (CEO, HQ, Founded, Website)
Table No 215: Purdue Pharma L.P. (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 216: Purdue Pharma L.P. (Net Income 2016-2019 (US$mn, AGR %))
Table No 217: Lavipharm. Profile (CEO, HQ, Founded, Website)
Table No 218: Lavipharm. (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 219: Lavipharm. (Net Income 2016-2019 (US$mn, AGR %))
Table No 220: Other Companies Transdermal Drug Delivery Market 2020 (Company, Location)
LIST OF FIGURES
Figure No 1: Transdermal Drug Delivery Market Application Overview
Figure No 2: Transdermal Drug Delivery Market Typer Overview
Figure No 3: Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 4: Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 5: Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 6: Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 7: Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 8: Transdermal Drug Delivery Submarket Forecast by Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure No 9: Transdermal Drug Delivery Submarket Forecast by Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 10: Transdermal Drug Delivery Submarket Forecast by Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 11: Transdermal Drug Delivery Submarket Forecast by Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 12: Transdermal Drug Delivery Submarket Forecast by Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 13: Pain management 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 14: Pain management 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 15: Pain management 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 16: Pain management 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 17: Pain management 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 18: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 19: Hormonal application Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 20: Hormonal application Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 21: Hormonal application Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 22: Hormonal application Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 23: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 24: Cardiovascular diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 25: Cardiovascular diseases Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 26: Cardiovascular diseases Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 27: Cardiovascular diseases Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 28: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 29: Central Nervous system disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 30: Central Nervous system disorders Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 31: Central Nervous system disorders Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 32: Central Nervous system disorders Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 33: Transdermal Drug Delivery Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure No 34: Transdermal Drug Delivery Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 35: Transdermal Drug Delivery Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 36: Transdermal Drug Delivery Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 37: Transdermal Drug Delivery Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 38: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 39: Transdermal Patches Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 40: Transdermal Patches Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 41: Transdermal PatchesSubmarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 42: Transdermal Patches Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 43: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 44: Transdermal Semisolids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 45: Transdermal Semisolids Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 46: Transdermal Semisolids Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 47: Transdermal Semisolids Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 48: Transdermal Drug Delivery Submarket Forecast by End users 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure No 49: Transdermal Drug Delivery Submarket Forecast by End users 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 50: Transdermal Drug Delivery Submarket Forecast by End users 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 51: Transdermal Drug Delivery Submarket Forecast by End users 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 52: Transdermal Drug Delivery Submarket Forecast by End users 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 53: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 54: Home Care Settings Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 55: Home Care Settings Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 56: Home Care Settings Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 57: Home Care Settings Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 58: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 59: Hospitals & Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 60: Hospitals & Clinics Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 61: Hospitals & Clinics Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 62: Hospitals & Clinics Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 63: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure No 64: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure No 65: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure No 66: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure No 67: Regional Transdermal Drug Delivery Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure No 68: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 69: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 70: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 71: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 72: North America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 73: North America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %)
Figure No 74: North America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 75: North America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 76: North America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 77: North America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 78: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 79: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 80: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 81: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 82: US Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 83: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %)
Figure No 84: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 85: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 86: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 87: Canada Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 88: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (Before COVID)
Figure No 89: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 90: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 91: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 92: Europe Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 93: Europe Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (Before COVID)
Figure No 94: Europe Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario V)
Figure No 95: Europe Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario U)
Figure No 96: Europe Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario W)
Figure No 97: Europe Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario L)
Figure No 98: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 99: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 100: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 101: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 102: UK Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 103: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %)
Figure No 104: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 105: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 106: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 107: Germany Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 108: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %)
Figure No 109: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 110: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 111: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 112: France Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 113: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 114: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 115: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 116: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 117: Rest of Europe Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 118: Asia-Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (Before COVID)
Figure No 119: Asia-Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 120: Asia-Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 121: Asia-Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 122: Asia-Pacific Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 123: Asia-Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M)
Figure No 124: Asia-Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario V)
Figure No 125: Asia-Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario U)
Figure No 126: Asia-Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario W)
Figure No 127: Asia-Pacific Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario L)
Figure No 128: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %)
Figure No 129: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 130: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 131: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 132: China Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 133: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %)
Figure No 134: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 135: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 136: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 137: India Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 138: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 139: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 140: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 141: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 142: Japan Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 143: Rest of APAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 144: Rest of APAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 145: Rest of APAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 146: Rest of APAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 147: Rest of APAC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 148: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M)
Figure No 149: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 150: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 151: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 152: Latin America Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 153: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M)
Figure No 154: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario V)
Figure No 155: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario U)
Figure No 156: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario W)
Figure No 157: Latin America Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario L)
Figure No 158: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 159: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 160: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 161: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 162: Brazil Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 163: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 164: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 165: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 166: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 167: Mexico Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 168: Rest of Latin America Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 169: Rest of Latin Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 170: Rest of Latin Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 171: Rest of Latin Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 172: Rest of Latin Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 173: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (Before COVID)
Figure No 174: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario V)
Figure No 175: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario U)
Figure No 176: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario W)
Figure No 177: Middle East Transdermal Drug Delivery Market Forecast by Application 2021-2031 (US$M) (COVID - Scenario L)
Figure No 178: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (Before COVID)
Figure No 179: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario V)
Figure No 180: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario U)
Figure No 181: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario W)
Figure No 182: Middle East Transdermal Drug Delivery Market Forecast by Typer2021-2031 (US$M) (COVID - Scenario L)
Figure No 183: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 184: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 185: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 186: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 187: GCC Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 188: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 189: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 190: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 191: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 192: South Africa Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 193: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure No 194: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure No 195: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure No 196: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure No 197: Rest of MEA Transdermal Drug Delivery Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure No 198: Hisamitsu Pharmaceutical Co., Inc. (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 199: Hisamitsu Pharmaceutical Co., Inc. (Net Income 2016-2019 (US$mn, AGR %)
Figure No 200: Mylan N.V (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 201: Mylan N.V (Net Income 2016-2019 (US$mn, AGR %)
Figure No 202: UCB S.A (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 203: UCB S.A (Net Income 2016-2019 (US$mn, AGR %)
Figure No 204: Novartis AG. (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 205: Novartis AG. (Net Income 2016-2019 (US$mn, AGR %))
Figure No 206: Glaxosmithkline PLC (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 207: Glaxosmithkline PLC (Net Income 2016-2019 (US$mn, AGR %))
Figure No 208: Boehringer Ingelheim International GmbH (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 209: Boehringer Ingelheim International GmbH (Net Income 2016-2019 (US$mn, AGR %))
Figure No 210: Johnson & Johnson (J&J). (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 211: Johnson & Johnson (J&J). (Net Income 2016-2019 (US$mn, AGR %))
Figure No 212: Endo International, Inc. (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 213: Endo International, Inc. (Net Income 2016-2019 (US$mn, AGR %))
Figure No 214: Purdue Pharma L.P (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 215: Purdue Pharma L.P (Net Income 2016-2019 (US$mn, AGR %))
Figure No 216: Lavipharm. (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 217: Lavipharm. (Net Income 2016-2019 (US$mn, AGR %))
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
